Skip to main content
. Author manuscript; available in PMC: 2022 Sep 28.
Published in final edited form as: Nat Cardiovasc Res. 2022 Mar 28;1(4):344–360. doi: 10.1038/s44161-022-00027-7

Extended Data Fig. 6. Different inhibitors suppressed the activation of TRPM2 by oxLDL or TSP1 treatment.

Extended Data Fig. 6

(a, b) Representative recording of TRPM2 current in HEK293T cells transfected with CD36 and TRPM2 during oxLDL treatment (50 μg/ml) as in a, and during TSP1 treatment (10 μg/ml) as in b. Transfected cells were treated with different inhibitors as indicated before current recording.